Citation, DOI, disclosures and article data
At the time the article was created Matt A. Morgan had no recorded disclosures.View Matt A. Morgan's current disclosures
Gadopentetate dimeglumine (also known as Magnevist) is an extracellular intravenous contrast agent used in magnetic resonance imaging.
linear, ionic molecule
100% renally excreted
T1 relaxivity @ 1.5 T: 3.9-4.3
concentration: 0.5 mmol/mL
recommended dosage: 0.1 mmol/kg
As an extracellular contrast agent, gadopentetate dimeglumine can be used in a wide range of MRI applications, including (but not limited to): hepatic imaging, pelvic imaging, cardiac imaging, brain and spine imaging, and musculoskeletal imaging.
There is an association between the use of gadolinium-based contrast agents (GBCAs) in patients with kidney dysfunction and nephrogenic systemic fibrosis (NSF), a rare, but serious, condition. As a result, the use of three GBCAs; gadopentetate dimeglumine (Magnevist), gadodiamide (Omniscan), and gadoversetamide (OptiMARK) are contraindicated in patients with acute kidney injury or with chronic, severe kidney disease 2.
- 1. Guglielmo FF, Mitchell DG, Gupta S. Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol. Clin. North Am. 2014;52 (4): 637-56. doi:10.1016/j.rcl.2014.02.004 - Pubmed citation
- 2. FDA. Information for healthcare professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). link: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney